Jay Toder
Rheumatology · Johnston, RINPI 1639249956
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $103,757 of the $138,720 with a category attached, or 74.8%. 9 manufacturers reported payments, led by Amgen at 38.4% of the total. Reporting peaked in 2019 at $97,727 and has fallen 99.8% since, to $175 in 2025. Among rheumatology clinicians in RI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 211 payments — averaging $657.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$53K
- Bristol Myers Squibb$45K
- AbbVie$22K
- Regeneron Healthcare Solutions, Inc.$9K
- Regeneron$6K
- Johnson & Johnson$1K
- plus $2K from 3 others
What the payments were for
- Consulting fees$10,9838%
- Speaking & faculty fees$103,75775%
- Travel & lodging$18,05313%
- Food & beverage$5,9124%
- Education$150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 61 | $53,213 |
| Bristol Myers Squibb | 50 | $44,873 |
| AbbVie | 57 | $22,459 |
| Regeneron Healthcare Solutions, Inc. | 17 | $9,490 |
| Regeneron | 12 | $5,892 |
| Johnson & Johnson | 1 | $1,250 |
| Sanofi | 2 | $1,232 |
| Hikma Pharmaceuticals USA | 10 | $186 |
| AstraZeneca | 1 | $125 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$138,720 in reported general payments places this provider in the 95th percentile of 22 rheumatology providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydroxychloroquine Sulfate | 16 | $546 |
| MethotrexateMethotrexate Sodium | 17 | $398 |
| Allopurinol | 20 | $223 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Johnston
- Edward ReardonWarwick$403K
- Deepan DalalCranston$122K
- Anthony ReginatoE. Providence$109K
- David KadmonLincoln$13K
- Christopher D ArcyWesterly$7K
- Jack MouradCranston$4K
- Vinit Joseph GilvazPawtucket$4K
- Wendy SilversmithWesterly$3K
- Edward LallyE. Providence$2K
- Ahmed EldibProvidence$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.